Annual Report 2017
Department of Pharmacy
Masakazu Yamaguchi, Toshikatsu Kawasaki, Mitsue Hirano, Yasuhiko Ichida, Tomoyuki Akimoto, Norio Goto, Reiko Matsui, Hisanaga Nomura, Daisuke Kano, Hideki Funasaki, Naoko Yoshino, Hiroko Kanaya, Shinya Suzuki, Nobuo Mochizuki, Tomoko Morita, Tomoka Okano, Kenji Kawasumi, Takeshi Koike, Ayumi Komuro, Yoshihiro Iwamoto, Takahiro Ohta, Akira Shinohara, Sayaka Nakajima, Misaki Takeno, Nobue Sato, Takayuki Sano, Daisuke Hisamatsu, Masaki Tanaka, Akira Tabei, Kanako Mamishin, Manami Asai, Takashi Igarashi, Tsuyoshi Uemoto, Hayato Kamata, Hirotaka Kikuchi, Ken Demachi, Kazuki Sugisaki
Introduction
The main objectives of the Department of Pharmacy are: (1) To promote clinical studies to create new evidence-based data; (2) To provide chemotherapy based on the most updated evidence-based data; and (3) To pursue patient-centered pharmaceutical care.
Our residency training program started in 2006. In 2017, six residents joined our department. Presently, we have a total of 18 residents. In addition, our department accepted six trainees from other institutions for our oncology pharmacist training programs during the period from January 2017 to March 2018. Through 2017, we educated five pharmacy students and one advanced-training pharmacy student.
The Department of Pharmacy provides various important services: controlling inventory, dispensing medications, preparing i.v. solutions for chemotherapy, which include the aseptic mixing of antineoplastic agents, collecting and providing drug information, managing therapeutic drug monitoring, checking treatment regimens for each patient's chemotherapy, and providing pharmaceutical management and counseling.
Our department reviews the drugs taken by patients before and during their hospitalization. In inpatient care, our department assigns pharmacists to provide medication counseling and drug information for healthcare providers and patients, and to pursue effective pharmaceutical care. In outpatient care, our department provides a pharmacy outpatient service in which pharmacists check patients for adverse reactions and doses of antineoplastic agents, especially in the case of oral anticancer medications. We then assess the necessity of supportive-care medications and suggest them to physicians. The pharmacy outpatient service also reviews the drugs taken by all patients to evaluate when patients have to stop their anticoagulants before their operation or when they have to stop to take metformin before examinations with iodinated-contrast material. Pharmacists are on duty at the Outpatient Chemotherapy Center as dedicated staff members. The pharmacists provide a Chemotherapy Hotline Service, which is a direct line for our outpatients who have any problems concerning their chemotherapy treatment. In the Outpatient Chemotherapy Center, pharmacists are always available to provide drug information for healthcare providers and patients. We also manage investigational drugs.
New developments
1) We started accepting pharmacist trainees from community pharmacy. We accepted three trainees for our 2.5 month oncology pharmacist training programs during the period from January 2017 to March 2018.
2) The National Cancer Center Hospital East (NCCHE) established the system of linked graduate school with Meiji Pharmaceutical University on October 31, 2017, and two pharmacy residents from our department are to be enrolled in the linked graduate school program from April 2018.
List of papers published in January 2017 - March 2018
Journal
1. Ikegawa K, Suzuki S, Nomura H, Enokida T, Yamazaki T, Okano S, Endo K, Saito S, Yamaguchi M, Tahara M. Retrospective analysis of premedication, glucocorticosteroids, and H1-antihistamines for preventing infusion reactions associated with cetuximab treatment of patients with head and neck cancer. J Int Med Res, 45:1378-1385, 2017
2. Hosokawa S, Inoue K, Kano D, Shimizu F, Koyama K, Nakagami Y, Muramatsu Y, Fukushi M. A simulation study for estimating scatter fraction in whole-body 18F-FDG PET/CT. Radiol Phys Technol, 10:204-212, 2017
3. Kano D, Nakagami Y, Kurihara H, Hosokawa S, Zenda S, Kusumoto M, Fujii H, Kaneta T, Saito S, Uesawa Y, Kagaya H. Development of a double-stranded siRNA labelling method by using 99mTc and single photon emission computed tomography imaging. J Drug Target, 25:172-178, 2017
4. Suzuki S, Chan A, Nomura H, Johnson PE, Endo K, Saito S. Chemotherapy regimen checks performed by pharmacists contribute to safe administration of chemotherapy. J Oncol Pharm Pract, 23:18-25, 2017
5. Ohta T, Mita M, Hishinuma S, Ishii-Nozawa R, Takahashi K, Shoji M. Inhibition of Ectopic Arginine Vasopressin Production by Phenytoin in the Small Cell Lung Cancer Cell Line Lu-165. Frontiers in endocrinology, 8:94, 2017
6. Sugama Y, Suzuki S, Kamata H, Suzuki H, Demachi K, Ikegawa K, Igarashi T, Yamaguchi M. Evaluation of clinical pharmacist collaborating service with oncologist at outpatient booth in cancer chemotherapy from a questionnaire survey. J Basic and Clin Pharm, 8:111-115, 2017
7. Suzuki S, Abbott R, Sakurai H, Kawasumi K, Johnson PE, Tahara M, Yamaguchi M, Saito S, Yee GC, Endo K. Evaluation of community pharmacist ability to ensure the safe use of oral anticancer agents: a nationwide survey in Japan. Jpn J Clin Oncol, 47:413-421, 2017
8. Suzuki S, Gilbar P, Yu B, Matsuyama C, Yamaguchi M. Current status of drug vial optimization use to prevent waste associated with injectable anticancer agents. J Oncol Pharm Pract, 1078155218758501, 2018
9. Suzuki S, Mochizuki N, Ikeuchi IA, Yoshida M, Murakami A, Ikegawa K, Yamaguchi M, Vigneron JH. Comparative evaluation of a website for drug incompatibility: Stabilis, Trissel's Handbook and the currently available tools in Japan. Eur J Oncol Pharm, 1:1-4, 2018